JD Health Likely to Continue Strong Growth in 2026 -- Market Talk

Dow Jones03-06 18:53

1053 GMT - JD Health could sustain strong growth into 2026, Jefferies analysts say in a note. They reckon the company's performance will continue to exceed market expectations, driven by new drug launches, margin expansion from marketing services and chronic patient management for pharmaceutical clients, and further monetization of its digital healthcare marketing business. The company is also developing full-stack AI capabilities to enhance the quality of its offerings, they add. Jefferies notes that management's 2026 guidance leaves significant room for operating leverage and net profit margin upside. It reiterates a buy rating on the stock, with a target price of HK$88.00. Shares last closed at HK$48.40. (jason.chau@wsj.com)

(END) Dow Jones Newswires

March 06, 2026 05:53 ET (10:53 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2617684379?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 18:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2617684379","market":"hk","top_or_hot":-1,"title":"JD Health Likely to Continue Strong Growth in 2026 -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1053 GMT - <a href=\"https://laohu8.com/S/JD\">JD</a> Health could sustain strong growth into 2026, Jefferies analysts say in a note. They reckon the company's performance will continue to exceed market expectations, driven by new drug launches, margin expansion from marketing services and chronic patient management for pharmaceutical clients, and further monetization of its digital healthcare marketing business. The company is also developing full-stack AI capabilities to enhance the quality of its offerings, they add. Jefferies notes that management's 2026 guidance leaves significant room for operating leverage and net profit margin upside. It reiterates a buy rating on the stock, with a target price of HK$88.00. Shares last closed at HK$48.40. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 06, 2026 05:53 ET (10:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>JD Health Likely to Continue Strong Growth in 2026 -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJD Health Likely to Continue Strong Growth in 2026 -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-06 18:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1053 GMT - <a href=\"https://laohu8.com/S/JD\">JD</a> Health could sustain strong growth into 2026, Jefferies analysts say in a note. They reckon the company's performance will continue to exceed market expectations, driven by new drug launches, margin expansion from marketing services and chronic patient management for pharmaceutical clients, and further monetization of its digital healthcare marketing business. The company is also developing full-stack AI capabilities to enhance the quality of its offerings, they add. Jefferies notes that management's 2026 guidance leaves significant room for operating leverage and net profit margin upside. It reiterates a buy rating on the stock, with a target price of HK$88.00. Shares last closed at HK$48.40. (jason.chau@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 06, 2026 05:53 ET (10:53 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2617684379","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2617684379","pubTimestamp":1772794380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1053 GMT - JD Health could sustain strong growth into 2026, Jefferies analysts say in a note. They reckon the company's performance will continue to exceed market expectations, driven by new drug launches, margin expansion from marketing services and chronic patient management for pharmaceutical clients, and further monetization of its digital healthcare marketing business. The company is also developing full-stack AI capabilities to enhance the quality of its offerings, they add. Jefferies notes that management's 2026 guidance leaves significant room for operating leverage and net profit margin upside. It reiterates a buy rating on the stock, with a target price of HK$88.00. Shares last closed at HK$48.40. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"86618":"京东健康-R","BK4588":"碎股","BK1142":"互联网与直销零售","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","LU0307460666.USD":"EASTSPRING INVESTMENTS CHINA EQUITY \"A\" ACC","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","BK4551":"寇图资本持仓","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","BK4509":"腾讯概念","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","LU1880383366.USD":"东方汇理中国股票基金 A2 (C)","BK1589":"北水核心资产","BK4220":"综合零售","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","BK4524":"宅经济概念","06618":"京东健康","BK1615":"港股-互联网","LU0051755006.USD":"摩根大通中国A (dist)","BK4531":"中概回港概念","IE0008368742.USD":"首域中国增长基金I Acc","LU1688375341.USD":"贝莱德中国灵活股票基金","BK1571":"互联网医疗","SG9999002463.SGD":"LionGlobal China Growth SGD","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK4526":"热门中概股","BK1515":"抗疫概念","BK4585":"ETF&股票定投概念","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","BK1591":"就地过年概念","BK4503":"景林资产持仓","BK1247":"药品零售","SGXZ86797644.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) INC","BK4122":"互联网与直销零售","BK1583":"高瓴概念","SGXZ62798434.SGD":"MAYBANK ASIAN GROWTH AND INCOME-I \"A\" (SGDHDG) ACC","BK4558":"双十一","BK4505":"高瓴资本持仓","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4614":"Manus概念股","KJD":"2倍做多JD ETF-KraneShares","IE00BGV7N243.SGD":"FSSA Global Emerging Markets Focus I Acc SGD","LU0106959298.USD":"UBS (LUX) EQUITY FUND - EMERGING MARKETS SUSTAINABLE LEADERS (USD) \"P\" (USD) ACC","BK4504":"桥水持仓","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","BK4579":"人工智能"},"translate_title":"京东健康2026年可能继续强劲增长——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"86618":0.6,"KJD":0.6,"06618":1.95},"content_text":"1053 GMT - JD Health could sustain strong growth into 2026, Jefferies analysts say in a note. They reckon the company's performance will continue to exceed market expectations, driven by new drug launches, margin expansion from marketing services and chronic patient management for pharmaceutical clients, and further monetization of its digital healthcare marketing business. The company is also developing full-stack AI capabilities to enhance the quality of its offerings, they add. Jefferies notes that management's 2026 guidance leaves significant room for operating leverage and net profit margin upside. It reiterates a buy rating on the stock, with a target price of HK$88.00. Shares last closed at HK$48.40. (jason.chau@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 06, 2026 05:53 ET (10:53 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2617684379","isCrawlerRequest":true}